急性脑梗死患者血浆S-100B和尿激酶型纤维溶酶原激活物测定及临床意义

The Measurement and Clinical Significance of Serm S-100B Protein and Urinary Plasminogen Activator in Patients with Brain Infarction

目的检测急性脑梗死(ACI)患者血浆中S-100B蛋白与尿激酶型纤维溶酶原激活物(uPA)含量变化,探讨其与脑梗死病情严重程度的相关性。方法ELISA法检测58例急性脑梗死患者(观察组)及30例同期住院的其他疾病患者(对照组)血浆S-100B和uPA含量。结果急性脑梗死患者血浆S-100B蛋白、uPA含量在急性期、恢复期与对照组比较差别有显著性意义(P<0.001)。S-100B和uPA含量与脑梗死程度均呈正相关(P<0.001);与神经功能缺损程度呈正相关(P<0.001)。结论检测脑梗死患者血浆S-100B和uPA对于判断脑梗死范围大小、病情变化及预后神经功能有一定临床意义。

Objective To measure the content change of S-100B protein and urokinase-type plasminogen activator (uPA )in the plasma of patients with cerebral infarction and to study its correlation with neurological deficits and infarct volume.Methods 58 patients with cerebral infarction in test group and 30 healthy persons in control group were measured for serum S-100B protein and uPA by enzyme-linked immunosorbent assay.Results Patients with acute cerebral infarction (ACI) had a higher concentration of serum S-100B protein and uPA than that in control group ( P <0.001).The concentration of serum S-100B protein and uPA were positively related to the volume of brain lesions and the neurological deficits outcome at hospital and.Conclusion Detecting the plasma S-100B protein and uPA has some clinical significance in judging the scope of ACI,disease change and prognostic neurosis.